Last reviewed · How we verify

Chewed ticagrelor

Centro Hospitalario La Concepcion · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Chewed ticagrelor is a Small molecule drug developed by Centro Hospitalario La Concepcion. It is currently FDA-approved.

Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a type of purinergic receptor. It is used to treat conditions such as Acute Coronary Syndrome, STEMI, and Acute Coronary Syndromes, often in conjunction with percutaneous coronary intervention.

At a glance

Generic nameChewed ticagrelor
SponsorCentro Hospitalario La Concepcion
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Chewed ticagrelor

What is Chewed ticagrelor?

Chewed ticagrelor is a Small molecule drug developed by Centro Hospitalario La Concepcion.

Who makes Chewed ticagrelor?

Chewed ticagrelor is developed and marketed by Centro Hospitalario La Concepcion (see full Centro Hospitalario La Concepcion pipeline at /company/centro-hospitalario-la-concepcion).

What development phase is Chewed ticagrelor in?

Chewed ticagrelor is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing